Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin’s lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.

双特异性抗体 (BsAb) 是一组新的靶向疗法，正在彻底改变 B 细胞非霍奇金淋巴瘤 (B-NHL) 的治疗格局。在复发/难治性情况下，挽救性化疗和自体干细胞移植能够治愈 50% 的患者，而另一半患者的结果却很惨淡，中位总生存期不到 12 个月。这种未满足的需求凸显了 BsAb 和 CAR-T 细胞疗法等创新疗法的重要性。在这篇综述中，我们深入研究了 B-NHL 中的 BsAb，从临床前开发到难治性和一线环境中的临床数据，然后讨论未来的前景。